NTLA: 1Q Update—Screening Resumed in the Ph3 ATTR Studies; Add'l Lonvo-z Data on Track for EAACI

Research evidence excerpt

NTLA: 1Q Update—Screening Resumed in the Ph3 ATTR Studies; Add'l Lonvo-z Data on Track for EAACI

Equity Research

Earnings Revised — May 11, 2026

Biotechnology

Intellia Therapeutics, Inc.

1Q Update—Screening Resumed in the Ph3 ATTR Studies; Equal Weight

Add'l Lonvo-z Data on Track for EAACI Price Target: $15.00

Notable Changes

Our Call $ (Dec) Current Prior % Chg

With HAE top-line data reported and ATTR MAGNITUDE & MAGNITUDE-2 study EPS 2026 (3.08) (3.78) 18.7%

screening activities advancing, focus is on HAE BLA filing completion in 2H26 and EPS 2027 (2.94) (3.63) 18.9%

enrollment progress for the ATTR studies. Rev. (MM) 2026 45.0 40.0 12.6%

Rev. (MM) 2027 72.3 68.9 4.9%

1Q26 earnings results. NTLA reported 1Q26 earnings today. Net loss per share was

($0.81) vs. consensus of ($0.91). The company ended the quarter with $517MM in cash Ticker NTLA

and marketable securities. Along with ~$207MM in gross proceeds from a follow-on Upside/(Downside) to Target (1.2)%

equity offering in April, NTLA expects its runway to extend into at least 2028(vs prior

Price (05/11/2026) $15.182H27). Our 2026/2027 EPS estimates are now ($3.08)/($2.94) vs. prior ($3.78)/($3.63).

52 Week Range $6.83 - 28.25

Lonvo-z for HAE. Recall, NTLA recently reported top-line data from the Ph3 HAELO Market Cap (MM) $1,760

study, meeting the primary endpoint of time-normalized investigator-confirmed HAE Enterprise Value (MM) $1,242

attacks from Wks 5–28 (prior note). NTLA will present add'l data on June 13th at EAACI Average Daily Value (MM) $74

(abs #100217) during the Immune deficiencies and autoimmunity session. On the Dividend Yield 0.0%

regulatory front, following initiation of a rolling BLA submission to FDA in April, NTLA is

on track to complete the submission in 2H26, with potential US launch in 1H27.